A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
12/2011
12/07/2011	CN101342203B 一种抗癌复方荔枝中药及其制备方法 A COMPOUND lychee anticancer medicine and its preparation method
12/07/2011	CN101249243B 一种治疗急性白血病的中药 A traditional Chinese medicine treatment of acute leukemia
12/07/2011	CN101232901B 磺酰胺化合物和血管生成抑制物质的联合新应用 Sulfonamide compound and angiogenesis inhibitory substances combined new applications
12/07/2011	CN101138612B 一种抗肿瘤制剂及其制备方法 An anti-tumor agent and its preparation method
12/07/2011	CN101134026B 长春瑞滨软胶囊及其制备方法和其应用 Vinorelbine soft capsule and its preparation method and its application
12/07/2011	CN101121934B 多靶点miRNA反义核苷酸的制备方法 Preparation of multi-target miRNA antisense nucleotides
12/07/2011	CN101121021B 人源化抗ErbB2抗体及用抗ErbB2抗体进行的治疗 Humanized anti-ErbB2 antibody treatment with anti-ErbB2 antibody and carried out
12/07/2011	CN101108245B 用于人肿瘤联合治疗的制剂及其用途 Combination therapy for human tumor preparation and use thereof
12/07/2011	CN101100483B 胞壁酰二肽的类似物 Muramyl peptide analogues
12/07/2011	CN101065485B Lna寡核苷酸和癌症治疗 Lna oligonucleotides and cancer treatment
12/07/2011	CN101054344B 脂氧素A<sub>4</sub>类似物 Lipoxin A <sub> 4 </ sub> analogue
12/07/2011	CN101049507B pitx3基因及其启动子的应用 pitx3 gene and its promoter application
12/06/2011	USRE43003 Epothilone derivatives
12/06/2011	US8071780 2-Hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
12/06/2011	US8071764 Compounds of reverse turn mimetics and the use thereof (2)
12/06/2011	US8071729 Anti-integrin antibodies, compositions, methods and uses
12/06/2011	US8071640 Urea oligomers, their preparation process and pharmaceutical compositions containing them
12/06/2011	US8071621 Alkylsulphonamide quinolines
12/06/2011	US8071620 Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors
12/06/2011	US8071616 Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
12/06/2011	US8071615 Carbonylamino-derivatives as novel inhibitors of histone deacetylase
12/06/2011	US8071609 Unsaturated heterocyclic derivatives
12/06/2011	US8071564 Regulation of angiogenesis with zinc finger proteins
12/06/2011	US8071550 Treating hyperplasic, hypertonic, cystic and/or neoplastic uterine gland tissue by local administration of a botulinum toxin or Clostridual neurotoxin
12/06/2011	US8071549 Compounds capable of affecting differentiation, proliferation, regeneration, plasticity and survival cells
12/06/2011	US8071547 Compositions of alpha-fetoprotein and inducers of apoptosis for the treatment of cancer
12/06/2011	US8071539 Albumin fusion proteins
12/06/2011	US8071366 Neural progenitor cells derived from whole bone marrow
12/06/2011	US8071333 Anti-integrin antibodies, compositions, methods and uses
12/06/2011	US8071294 Cancer therapy sensitizer
12/06/2011	US8071087 Reovirus for the treatment of cellular proliferative disorders
12/06/2011	US8071072 Cytotoxicity mediation of cells evidencing surface expression of CD44
12/06/2011	CA2626032C Camptothecin derivatives as chemoradiosensitizing agents
12/06/2011	CA2603809C Radiotherapy enhancer
12/06/2011	CA2566299C Recombinant chemotactic antigen gene vaccine
12/06/2011	CA2538748C Cobalamin conjugates for anti-tumor therapy
12/06/2011	CA2523063C 7-azaindoles and the use thereof as therapeutic agents
12/06/2011	CA2515940C Substituted heterocycles
12/06/2011	CA2501774C 2" oxo-voruscharin and derivatives thereof
12/06/2011	CA2485430C Process for the preparation of a hydrate of an anthranilic acid derivative
12/06/2011	CA2485351C Cyanoguanidine prodrugs
12/06/2011	CA2455620C Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
12/06/2011	CA2448482C Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket
12/06/2011	CA2432027C Novel bifunctional chelating compounds containing hydroxamic acid residues
12/06/2011	CA2387922C Inhibition of cell motility and angiogenesis
12/06/2011	CA2383522C Neurotherapeutic composition and method
12/06/2011	CA2333306C Peptides based on the sequence of human lactoferrin and their use
12/06/2011	CA2328783C Human procalcitonin and the preparation and use thereof
12/06/2011	CA2309954C Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
12/06/2011	CA2305683C Immunogenic peptides from the hpv e7 protein
12/06/2011	CA2301333C Prb2/p130 peptide inhibitors of cdk2 kinase activity
12/06/2011	CA2250164C Oncofetal antigen specific t-lymphocyte mediated immune response: manipulation and uses of oncofetal antigen specific cd4, cd8 cytotoxic and suppressor t cells and interleukin-10
12/04/2011	CA2799391A1 Improved process for a folate-targeted agent
12/04/2011	CA2725027A1 Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
12/04/2011	CA2725026A1 Methods of treating platinum-sensitive recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
12/01/2011	WO2011150418A2 Compositions and methods for treating pathologies
12/01/2011	WO2011150356A1 Heterocyclic compounds as janus kinase inhibitors
12/01/2011	WO2011150347A2 Non-peptide bdnf neurotrophin mimetics
12/01/2011	WO2011150320A2 Activators of innate immunity
12/01/2011	WO2011150279A2 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-trna synthetases
12/01/2011	WO2011150264A2 Synthetic nanocarrier combination vaccines
12/01/2011	WO2011150229A2 Dietary supplements containing extracts of cinnamon and methods of using same to promote enhanced sirtuin, cell and telomere integrity
12/01/2011	WO2011150198A1 Azolyl urea compounds and methods of use thereof
12/01/2011	WO2011150094A2 Tumor suppression compositions
12/01/2011	WO2011150082A2 Methods of utilizing the arrestin-2/stam-1 complex as a therapeutic target
12/01/2011	WO2011150022A2 Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
12/01/2011	WO2011149909A2 Class i mhc phosphopeptides for cancer immunotherapy and diagnosis
12/01/2011	WO2011149878A1 An aminopyrazole triazolothiadiazole inhibitor of c-met protein kinase
12/01/2011	WO2011149841A1 SUBSTITUTED THIAZOLIDINEDIONE INDAZOLES, INDOLES AND BENZOTRIAZOLES AS ESTROGEN-RELATED RECEPTOR-α MODULATORS
12/01/2011	WO2011149824A1 Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
12/01/2011	WO2011149354A1 Mirnas involved in the blood brain barrier function
12/01/2011	WO2011149250A2 Tricarbonyl technetium-99m or rhenium-188 label ring rgd derivative, a preparation method thereof, and a pharmaceutical composition containing the derivative as an active ingredient for use in the diagnosis or treatment of angiogenesis-related diseases
12/01/2011	WO2011149173A1 Novel anticancer agents comprising peptides with cancer-specific toxicity
12/01/2011	WO2011149134A1 Anticancer composition
12/01/2011	WO2011149051A1 Antitumor t cell response enhancer
12/01/2011	WO2011149046A1 Therapeutic agent for pancreatic cancer
12/01/2011	WO2011149011A1 Novel indazole derivative or salt thereof, manufacturing intermediate therefor, antioxidant using same, and use for an indazole derivative or salt thereof
12/01/2011	WO2011148956A1 Fused imidazole derivative
12/01/2011	WO2011148124A1 Novel iridium/rhodium anti-cancer compounds
12/01/2011	WO2011148116A2 Modified hyaluronic acid, method for manufacturing same and uses thereof
12/01/2011	WO2011148083A1 Peptide for use as a medicament, in particular for the treatment of cancer
12/01/2011	WO2011147764A1 Thieno (2, 3b) pyrazine compounds as b - raf inhibitors
12/01/2011	WO2011147762A2 Stabilized radiopharmaceutical composition
12/01/2011	WO2011147528A1 Biguanide compounds and its use for treating cancer
12/01/2011	WO2011147330A1 Chemical synthesis and anti-tumor and anti-metastatic effects of dual functional conjugate
12/01/2011	WO2011147296A1 Pyrazole derivatives
12/01/2011	WO2011147254A1 Phenylbutyryl curcumin derivatives and uses for preparing anti-tumor drugs thereof
12/01/2011	WO2011147231A1 Medicinal composition for treating leukemia, preparing method and use thereof
12/01/2011	WO2011147198A1 Compounds and methods for treatment of proliferative diseases
12/01/2011	WO2011147138A1 Targeting fusion protein of interleukin and preparation method and use thereof
12/01/2011	WO2011147102A1 Synthetic method for 6,7-substituents-4-aniline quinazoline
12/01/2011	WO2011147086A1 Microvesicles carrying small interfering rnas, preparation methods and uses thereof
12/01/2011	WO2011147066A1 Arylamino purine derivatives, preparation method and pharmaceutical use thereof
12/01/2011	WO2011147057A1 Anti-angiogenic fusion polypeptide, gene and use thereof
12/01/2011	WO2011147038A1 Heterocyclyl-pyridinyl-based biphosphonic acid, pharmaceutically acceptable salt thereof, composition thereof and method of use thereof
12/01/2011	WO2011147012A1 Compositions comprising botanicals, including the use and method of use thereof
12/01/2011	WO2011127058A8 Biomarkers for mdm2 inhibitors for use in treating disease
12/01/2011	WO2011113892A3 Combined use of phospholipid and sulfate groups-carrying polysaccharides for inhibiting metastatic spread
12/01/2011	WO2011112953A3 Use of erbb3 inhibitors in the treatment of triple negative and basal-like breast cancers
12/01/2011	WO2011100769A3 Kinase modulators for the treatment of cancer

1 ... 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 ... 2211